Topics

NICE Draft Guidance: Rejects Keytruda In Head & Neck Cancer, Xospata In AML

07:54 EST 15 Jan 2020 | SCRIP

A series of decisions on anticancer drugs from the UK’s NICE will act as a reminder to drug developers excited...

      

Related Stories

 

Original Article: NICE Draft Guidance: Rejects Keytruda In Head & Neck Cancer, Xospata In AML

NEXT ARTICLE

More From BioPortfolio on "NICE Draft Guidance: Rejects Keytruda In Head & Neck Cancer, Xospata In AML"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...